Perspectives
Biologics dominate treatment costs for Crohn’s and ulcerative colitis
BIologic drug therapy makes up more than 70% of the total cost of care for either condition
October 19, 2019Biologic therapy makes up more than 70% of the total cost of care for members with either Crohn’s disease (CD) or ulcerative colitis (UC)
Crohn’s disease and ulcerative colitis are the two major types of inflammatory bowel disease (IBD). This study determined that biologic therapy makes up most of the annual total pharmacy and medical costs. It shows real-world prevalence, utilization, and total health care costs to improve understanding of the conditions. It adds Prime’s insights to the industry dialogue tying drug cost to value. But it’s clear that it is not possible to obtain a direct medical care cost offset to biologic therapy in IBD.
Related news
Perspectives
March 27, 2024
Drug Approvals Monthly Update: March 2024
Critical updates in an ever-changing environment
Perspectives
March 27, 2024
Clinical News: March 2024
Your monthly source for drug information highlights
Perspectives
March 14, 2024
High-Cost Therapy Profile
Detailed information about Sotatercept Subcutaneous (SC)